Neovacs CEO: 'We Need A Phase III Partner Now' To Progress Our Lupus Asset
French biotech says it has adequate Phase II data to design a pivotal study with regulators, but needs trial funding and a big pharma partner.
You may also be interested in...
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.